Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

Clin Infect Dis. 1997 Dec;25(6):1465-7. Unique Identifier : AIDSLINE MED/98093424
Munsiff SS; Joseph S; Ebrahimzadeh A; Frieden TR; City of New York Department of Health, New York 10007, USA.

Abstract: All New York City patients whose cultures yielded Mycobacterium tuberculosis with isolated resistance to rifampin in 1993 and 1994 were included in this study. Of the 96 patients, 48 (50%) had primary resistance, 32 (33%) had acquired resistance, and 16 17%) had unclassified resistance; 66% had histories of illicit drug use, and 79% were infected with human immunodeficiency virus HIV). The median time to emergence of resistance was 40 weeks among the 32 patients with acquired resistance. Each of the HIV-infected patients with acquired resistance (cases, n = 29) was matched to two HIV-infected patients who had disease due to fully susceptible M. tuberculosis (controls, n = 58). In multivariate analysis, factors associated with the emergence of rifampin resistance were as follows: a sputum smear positive for acid-fast bacilli, advanced immunosuppression, and nonadherence to therapy.

Keywords: *Antibiotics, Antitubercular/PHARMACOLOGY *Mycobacterium tuberculosis/DRUG EFFECTS *Rifampin/PHARMACOLOGY *Tuberculosis/DRUG THERAPY
980430
M9841847

ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGiS, or the party credited as the provider of the content.